Generics Conference (Generics)

Venue: BSG Conference Centre

Location: London, United Kingdom

Event Date/Time: Apr 21, 2009 End Date/Time: Apr 21, 2009
Report as Spam


The global market for generic drugs is forecast to double in the next
15 years, as healthcare providers shift from more expensive branded
medicines to more cost-effective generic drugs.

Healthcare providers are increasingly switching to generic medicines to combat
rising healthcare costs. This shift will help governments improve their provision
of wider and better healthcare options. Aging populations worldwide are
creating a growing market for drugs for chronic conditions, notably statins and
antihypertensive drugs for cardiovascular disorders and drugs for Parkinson’s and
Alzheimer’s diseases. Increased demand in this area will provide additional revenue
opportunities for both foreign and domestic generic pharmaceutical manufacturers.
Recent years have witnessed a large number of merger and acquisition (M&A)
activities within the generic pharmaceutical industry. High profi le deals highlight
this trend, and emphasise how rapid expansion is encouraged in such a successful
market. All of the leading generic companies have been involved in some M&A
activity in order to gain advantage over their competitors. Initiating mergers
and acquisitions can provide signifi cant advantages, either by gaining access to
a rapidly growing market, such as those in Central and Eastern Europe, or by
enhancing a company’s production capabilities.
Competition within the generics market is becoming increasingly fi erce with ever
more companies entering the market. Generics manufacturers need to be aware of
which branded products and formulations to target in order to receive the greatest
return on investment. From 2008-2010 a total of 36 key drugs are expected to
lose patent protection.
Reasons to register:
• How did we get to the situation we are at now? - Examining the current legal
patent/IP framework
• Examine the regulatory, policy, clinical consideration and implications of
biosimilars: US perspective
• Assess the current legal hurdles in developing generic drugs and hear an updates
on the changes confronting European & US market development
• Is regulation affecting the innovation of new pharmaceutical products?
• Identify the drivers of an increasing generic market
• Understand the legal challenges and scientifi c requirements and economics to
accelerate marketing entry
• Engage with a distinguished audience that will enhance your reputation as a key
player in the revolutionary market of generics


226-236 City Road
United Kingdom

Additional Information

Standard Prices: Conference only Fee: £999 VAT: £149.85 Total: £1148.85 Promotional Literature Distribution (Distribution of your company’s promotional literature to all conference attendees) Fee: £799 VAT: £119.85 Total: £918.85